Gena Wang
Stock Analyst at Barclays
(2.25)
# 2,661
Out of 4,893 analysts
203
Total ratings
40.3%
Success rate
-2.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $51 → $57 | $42.83 | +33.08% | 10 | Jul 1, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $89 → $29 | $19.37 | +49.72% | 10 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $57 → $59 | $31.27 | +88.68% | 3 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $5.52 | +81.16% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.53 | +850.39% | 4 | May 14, 2025 | |
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.63 | +146.15% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $60.08 | -30.09% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $4.43 | +758.76% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $48.74 | -13.83% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $36.63 | +44.71% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $9.06 | +21.41% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $31 → $25 | $21.46 | +16.50% | 9 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $40 | $32.79 | +21.99% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.93 | +422.77% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $12.13 | +114.34% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $478.97 | -2.50% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.08 | -2.60% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $4.44 | -9.91% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $320.87 | +2.53% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $59.67 | +44.13% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $9.17 | +445.26% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $41.44 | +95.46% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $39.46 | +138.25% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $13.57 | -33.68% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $14.79 | +69.03% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.37 | +115.18% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.60 | +150.00% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.83 | +4,616.98% | 1 | Jan 6, 2017 |
Ionis Pharmaceuticals
Jul 1, 2025
Upgrades: Overweight
Price Target: $51 → $57
Current: $42.83
Upside: +33.08%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Overweight
Price Target: $89 → $29
Current: $19.37
Upside: +49.72%
Avidity Biosciences
Jun 10, 2025
Maintains: Overweight
Price Target: $57 → $59
Current: $31.27
Upside: +88.68%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $5.52
Upside: +81.16%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.53
Upside: +850.39%
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.63
Upside: +146.15%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $60.08
Upside: -30.09%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $4.43
Upside: +758.76%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $48.74
Upside: -13.83%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $36.63
Upside: +44.71%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $9.06
Upside: +21.41%
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $21.46
Upside: +16.50%
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $32.79
Upside: +21.99%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.93
Upside: +422.77%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $12.13
Upside: +114.34%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $478.97
Upside: -2.50%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.08
Upside: -2.60%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $4.44
Upside: -9.91%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $320.87
Upside: +2.53%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $59.67
Upside: +44.13%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $9.17
Upside: +445.26%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $41.44
Upside: +95.46%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $39.46
Upside: +138.25%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.57
Upside: -33.68%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $14.79
Upside: +69.03%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.37
Upside: +115.18%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.60
Upside: +150.00%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.83
Upside: +4,616.98%